Evidence map›Paper›PMID 34460078›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2021

Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.

Kun Wu, Yuan-Yuan Mao, Qi Chen, Bolin Zhang, Sheng Zhang, Han-Jiang Wu, Yan Li

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. DuringAutophagy reports · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. HIF-1 signaling: an emerging mechanism for mitochondrial dynamics.Journal of physiology and biochemistry · 2023
    Review
  14. The PRAK-NRF2 axis promotes the differentiation of Th17 cells by mediating the redox homeostasis and glycolysis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kun WuDepartment of Stomatology, Second Xiangya Hospital, Central South University, Renmin road, No. 139, Changsha, 410011, Hunan, China.
Yuan-Yuan MaoDepartment of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qi ChenDepartment of Stomatology Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Bolin ZhangDepartment of Stomatology, Xinhua Hospital Affiliated To Shanghai Jiao Tong University, Shanghai, China.
Sheng ZhangDepartment of Stomatology, Second Xiangya Hospital, Central South University, Renmin road, No. 139, Changsha, 410011, Hunan, China. drzhangsheng@csu.edu.cn.
Han-Jiang WuDepartment of Stomatology, Second Xiangya Hospital, Central South University, Renmin road, No. 139, Changsha, 410011, Hunan, China. wuhanjiang@csu.edu.cn.
Yan LiPrecision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 650 Xin Songjia Road, Shanghai, 200025, China. liyan1106369@163.com.ORCID http://orcid.org/0000-0002-4777-5060
Central South University · CNShanghai Jiao Tong University · CNFudan University · CN

Funding

Natural Science Foundation of China 81902808
6 · The paper itself

Abstract

purposeChemotherapy based on cisplatin (CDDP) has been established as the treatment of choice for head and neck squamous cell carcinoma (HNSCC). Malignant tumors respond to microenvironmental alterations through a dynamic balance between mitochondrial fission and fusion. HNSCCs are known to exhibit hypoxic conditions, yet the respective effects and underlying mechanisms of hypoxia on chemosensitivity and mitochondrial dynamics remain to be resolved.

methodsThe effect of hypoxia on the chemosensitivity of HNCC cells was determined by flow cytometry. Mitochondrial fission factor (Mff) expression was assessed by RT-PCR and Western blotting in hypoxic HNSCC cells, and further verified in primary CDDP-sensitive and CDDP-resistant HSNCC samples. The biological function of Mff was evaluated by loss of function and gain of function analyses, both in vitro and in vivo.

resultsWe found that hypoxia promoted mitochondrial fission and CDDP sensitivity in HNSCC cells. Importantly, Mff was found to be correlated with chemosensitivity in primary clinical samples under hypoxic conditions. Hypoxia-inducible factor 1α (HIF-1α) was found to markedly increase Mff transcription and to directly bind to Mff. Hypoxia enhanced the release of reactive oxygen species (ROS) and upregulated the expression of Mff via HIF-1α in HNSCC cells. ROS depletion in HNSCC cells attenuated HIF-1α expression, Mff expression and mitochondrial fission. Moreover, Mff knockdown led to suppression of hypoxia-induced mitochondrial fission and to decreased CDDP chemosensitivity in vivo and in vitro.

conclusionsOur findings indicate that hypoxia-induced release of ROS can promote mitochondrial fission and CDDP chemosensitivity via HIF1α/Mff regulation in HNSCC cells, indicating that Mff may serve as a biomarker to predict neoadjuvant chemosensitivity in HNSCC patients and as a target for overcoming chemoresistance.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, Squamous CellCell Line, TumorCell SurvivalCisplatinGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHEK293 CellsHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitMembrane ProteinsMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentsCisplatinHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMembrane ProteinsMff protein, humanMitochondrial ProteinsReactive Oxygen SpeciesCisplatin sensitivityHead and neck squamous cell carcinomaHypoxiaMitochondrial fissionROS

Identifiers

PMID34460078
PMCPMC12980785
OpenAlexW3198386121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.